SCHEMBL4319807

SCHEMBL4319807

COCCOc1ccc(/C=C/c2n[nH]c3ccccc23)c(NC(=O)c2sccc2C)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 4/20 0.55
▸ AURKB Q96GD4 3/20 0.55
▸ NPC1 O15118 4/20 0.40
▸ RAB9A P51151 4/20 0.40
▸ SNCA P37840 1/20 0.40
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ HPGD P15428 1/20 0.38
▸ KDR P35968 3/20 0.37
▸ FGFR1 P11362 2/20 0.37
▸ FLT3 P36888 2/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4319811 1.00 AURKA (0.55) AURKAAURKBNPC1RAB9ASNCA
SCHEMBL4312994 0.87 AURKA (0.62) AURKAAURKBNPC1RAB9AMEN1
SCHEMBL4312987 0.87 AURKA (0.62) AURKAAURKBNPC1RAB9AMEN1
SCHEMBL4308978 0.87 AURKB (0.56) AURKAAURKBALDH1A1SMN1; SMN2KDR
SCHEMBL4308984 0.87 AURKB (0.56) AURKAAURKBALDH1A1SMN1; SMN2KDR
SCHEMBL4313356 0.85 AURKA (0.56) AURKAAURKBNPC1RAB9ASNCA
SCHEMBL4313350 0.85 AURKA (0.56) AURKAAURKBNPC1RAB9ASNCA
SCHEMBL4313400 0.85 AURKA (0.58) AURKAAURKBNPC1RAB9AMEN1
SCHEMBL4313389 0.85 AURKA (0.58) AURKAAURKBNPC1RAB9AMEN1
SCHEMBL4317413 0.85 AURKA (0.56) AURKAAURKBNPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 — — US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 — — US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885NPC1 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback